Asandeutertinib vs H002

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Asandeutertinib

Marketed by TYK Medicines, Inc.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05146219 · Phase 2 · completed

The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2027 · NCT06672068 (registry estimate)

Reported efficacy

Intracranial Overall Response Rate (iORR) (13 months.); Extracranial Overall Response Rate (eORR) (13 months.): Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months (not_applicable)

Result source: NCT05146219

H002

Developed by RedCloud Bio

Phase 1/2 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05519293 · Phase 1/2 · status unknown

A non-randomized, open-label, sequential-cohort phase 1/2 study of H002 with an estimated 76 participants and no results posted to the registry. With no comparator arm and no posted results, this is weak evidence.

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAsandeutertinibH002
PFS, median—Trial running · NCT05382728—Not reported
OS, median—Trial running · NCT05382728—Not reported
ORR—Trial running · NCT05382728—Not reported
Duration of response, median—Trial running · NCT05382728—Not reported

PFS, median

Asandeutertinib
—Trial running · NCT05382728
H002
—Not reported

OS, median

Asandeutertinib
—Trial running · NCT05382728
H002
—Not reported

ORR

Asandeutertinib
—Trial running · NCT05382728
H002
—Not reported

Duration of response, median

Asandeutertinib
—Trial running · NCT05382728
H002
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

H002: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Asandeutertinib
Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months NCT05146219 · Phase 2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asandeutertinib's landscape · H002's landscape